Sally Temple, Ph.D., named to National Academy of Medicine

press release
Written By Mediaspace

Luxa Biotechnology LLC, a joint venture between Y2 Solution and the U.S.-based Neural Stem Cell Institute (NSCI), is currently conducting a clinical trial in the United States for the development and commercialization of a treatment for Dry Age-related Macular Degeneration.

Sally Temple, Ph.D., R&D Director at Luxa Biotechnology and the first to identify and characterize neural stem cells, was elected as a member of the National Academy of Medicine (NAM) in 2022. NAM, an American nonprofit and non-governmental organization, provides international advice on issues related to medicine, health policy, and biomedical science. It aims to deliver unbiased, evidence-based recommendations to policy-makers, professionals, and leaders across all sectors of society.

Membership in NAM is considered one of the highest honors in the fields of health and medicine, recognizing individuals for outstanding professional achievements and a commitment to service.

 

The article  

 https://nam.edu/national-academy-of-medicine-elects-100-new-members-2022/

 https://issuu.com/umkelloggeyecenter/docs/annual_report_online_version/s/18264093

Mediaspace https://mediaspace.co
Previous

The Report of the Annual Meeting hosted by the National Eye Institute in the United States has been released
Next

Luxa Biotechnology gives first dose to patients in clinical trial